Globus Medical Inc. Class A Common Stock vs Kraft Heinz Co — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Kraft Heinz Co trades at $22.99 (market cap $26.60B). The key difference: Kraft Heinz Co is far larger — about 2.6× Globus Medical Inc. Class A Common Stock's market cap, and Kraft Heinz Co pays a 7.13% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Kraft Heinz Co for 129 Days on average.
| GMED | KHC | |
|---|---|---|
Market Cap | $10.25B | $26.60B |
Volume | 1,108,124 | 11,136,448 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $27.62 |
52-Week Low | $58.33 | $21.21 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $9.76B | $42.92B |
Dividend Yield | — | 7.13% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Kraft Heinz (KHC) trades at $22.43, down 0.09% with bearish technical signals despite recent earnings beats. The company faces fundamental challenges with a net loss of $5.85 billion in 2025 and negative profit margins, though operating cash flow remains strong at $4.46 billion. Recent news highlights ongoing turnaround efforts including new product launches and a $700 million reinvestment strategy to revive brands.
The stock presents a mixed outlook with attractive valuation metrics (P/E 13.04, P/B 0.74) and 6.5% dividend yield, but significant execution risks persist. Analyst consensus leans cautious with 57% hold ratings, while institutional interest remains with recent large purchases. Key risks include continued volume declines, high debt load, and competitive pressures in the consumer goods sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →